Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/05/13 | 936 | 958 | 923 | 932 | +3 | +0.3% | 172,100 |
| 2022/05/12 | 961 | 966 | 917 | 929 | -54 | -5.5% | 179,500 |
| 2022/05/11 | 965 | 1,016 | 952 | 983 | +18 | +1.9% | 143,300 |
| 2022/05/10 | 975 | 985 | 938 | 965 | -40 | -4% | 294,300 |
| 2022/05/09 | 1,030 | 1,044 | 985 | 1,005 | -44 | -4.2% | 220,900 |
| 2022/05/06 | 1,092 | 1,102 | 1,040 | 1,049 | -60 | -5.4% | 157,500 |
| 2022/05/02 | 1,112 | 1,137 | 1,095 | 1,109 | -17 | -1.5% | 60,400 |
| 2022/04/28 | 1,110 | 1,134 | 1,081 | 1,126 | +42 | +3.9% | 69,600 |
| 2022/04/27 | 1,112 | 1,120 | 1,060 | 1,084 | -58 | -5.1% | 240,400 |
| 2022/04/26 | 1,160 | 1,167 | 1,120 | 1,142 | -10 | -0.9% | 108,400 |
| 2022/04/25 | 1,175 | 1,204 | 1,150 | 1,152 | -55 | -4.6% | 84,200 |
| 2022/04/22 | 1,181 | 1,207 | 1,161 | 1,207 | +8 | +0.7% | 54,200 |
| 2022/04/21 | 1,215 | 1,215 | 1,182 | 1,199 | -25 | -2% | 38,000 |
| 2022/04/20 | 1,230 | 1,248 | 1,207 | 1,224 | +2 | +0.2% | 36,600 |
| 2022/04/19 | 1,217 | 1,241 | 1,203 | 1,222 | +13 | +1.1% | 28,300 |
| 2022/04/18 | 1,200 | 1,221 | 1,183 | 1,209 | -8 | -0.7% | 30,800 |
| 2022/04/15 | 1,189 | 1,219 | 1,177 | 1,217 | +8 | +0.7% | 44,800 |
| 2022/04/14 | 1,213 | 1,235 | 1,185 | 1,209 | +2 | +0.2% | 79,100 |
| 2022/04/13 | 1,161 | 1,209 | 1,160 | 1,207 | +50 | +4.3% | 67,200 |
| 2022/04/12 | 1,158 | 1,187 | 1,146 | 1,157 | -29 | -2.4% | 86,900 |
| 2022/04/11 | 1,197 | 1,205 | 1,153 | 1,186 | -21 | -1.7% | 86,200 |
| 2022/04/08 | 1,180 | 1,211 | 1,180 | 1,207 | +41 | +3.5% | 61,100 |
| 2022/04/07 | 1,186 | 1,192 | 1,152 | 1,166 | -44 | -3.6% | 95,400 |
| 2022/04/06 | 1,235 | 1,235 | 1,183 | 1,210 | -40 | -3.2% | 154,800 |
| 2022/04/05 | 1,249 | 1,271 | 1,232 | 1,250 | +18 | +1.5% | 99,700 |
| 2022/04/04 | 1,241 | 1,244 | 1,207 | 1,232 | -18 | -1.4% | 123,200 |
| 2022/04/01 | 1,275 | 1,277 | 1,236 | 1,250 | -30 | -2.3% | 51,400 |
| 2022/03/31 | 1,293 | 1,300 | 1,251 | 1,280 | -15 | -1.2% | 77,300 |
| 2022/03/30 | 1,288 | 1,295 | 1,253 | 1,295 | +48 | +3.8% | 74,700 |
| 2022/03/29 | 1,233 | 1,273 | 1,233 | 1,247 | +22 | +1.8% | 57,800 |
| 2022/03/28 | 1,266 | 1,266 | 1,220 | 1,225 | -70 | -5.4% | 88,400 |
| 2022/03/25 | 1,355 | 1,360 | 1,288 | 1,295 | -49 | -3.6% | 69,100 |
| 2022/03/24 | 1,300 | 1,350 | 1,277 | 1,344 | +36 | +2.8% | 80,900 |
| 2022/03/23 | 1,320 | 1,355 | 1,308 | 1,308 | +5 | +0.4% | 120,400 |
| 2022/03/22 | 1,324 | 1,324 | 1,274 | 1,303 | +6 | +0.5% | 116,100 |
| 2022/03/18 | 1,254 | 1,302 | 1,247 | 1,297 | +33 | +2.6% | 145,500 |
| 2022/03/17 | 1,249 | 1,276 | 1,233 | 1,264 | +43 | +3.5% | 169,300 |
| 2022/03/16 | 1,195 | 1,235 | 1,179 | 1,221 | +41 | +3.5% | 185,700 |
| 2022/03/15 | 1,168 | 1,192 | 1,131 | 1,180 | -9 | -0.8% | 130,900 |
| 2022/03/14 | 1,174 | 1,207 | 1,144 | 1,189 | +6 | +0.5% | 181,800 |
| 2022/03/11 | 1,230 | 1,260 | 1,150 | 1,183 | -17 | -1.4% | 562,000 |
| 2022/03/10 | 1,202 | 1,230 | 1,104 | 1,200 | +28 | +2.4% | 703,100 |
| 2022/03/09 | 1,388 | 1,404 | 1,172 | 1,172 | -400 | -25.4% | 1,261,200 |
| 2022/03/08 | 1,568 | 1,636 | 1,547 | 1,572 | -4 | -0.3% | 193,200 |
| 2022/03/07 | 1,605 | 1,615 | 1,550 | 1,576 | -85 | -5.1% | 206,800 |
| 2022/03/04 | 1,730 | 1,730 | 1,622 | 1,661 | -98 | -5.6% | 299,500 |
| 2022/03/03 | 1,830 | 1,862 | 1,735 | 1,759 | -42 | -2.3% | 331,700 |
| 2022/03/02 | 1,759 | 1,827 | 1,729 | 1,801 | +2 | +0.1% | 217,800 |
| 2022/03/01 | 1,755 | 1,844 | 1,751 | 1,799 | +60 | +3.5% | 196,800 |
| 2022/02/28 | 1,622 | 1,755 | 1,619 | 1,739 | +52 | +3.1% | 242,200 |
751～
800
件表示中 / 1619件
類似銘柄と比較する
現在ご覧いただいている「ＤＥＬＴＡ－Ｐ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＤＥＬＴＡ－Ｐ | 63,300円 | - | - | 0.00% | - | 22.40倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| 日ケミファ | 147,000円 | +7.5% | -77.4% | 3.40% | 35.36倍 | 0.28倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| クリングル | 90,800円 | +240.0% | - | 0.00% | - | 3.92倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| カルナバイオ | 32,000円 | +13.5% | - | 0.00% | - | 2.47倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| モダリス | 7,800円 | - | - | 0.00% | - | 1.66倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
市場注目の銘柄
チャート関連のコラム
